Lifecare AS Cash Flow Conversion Efficiency
Lifecare AS cash flow conversion efficiency. Based on the latest financial reports, Lifecare AS (LIFE) has a cash flow conversion efficiency ratio of -0.228x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-12.41 Million ≈ $-1.31 Million USD) by net assets (Nkr54.47 Million ≈ $5.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lifecare AS (2017–2025)
Cash flow conversion efficiency of Lifecare AS from 2017 to 2025. This chart illustrates how Lifecare AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LIFE share price today for real-time trading data and today's change.
Lifecare AS Cash Flow Conversion Ratio Explained
Lifecare AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lifecare AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lifecare AS ranked by their cash flow conversion efficiency. Also see LIFE market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crunchfish AB
ST:CFISH
|
-0.084x |
|
Quartz Mountain Resources Ltd
V:QZM
|
-0.198x |
|
BMG Resources Ltd
AU:BMG
|
-0.022x |
|
Les Enphants Co Ltd
TW:2911
|
-0.426x |
|
Alphawave IP Group PLC
LSE:AWE
|
-0.107x |
|
Thai Nondestructive Testing Public Company Limited
BK:TNDT
|
0.057x |
|
Leeuwin Metals Ltd
AU:LM1
|
-0.042x |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
0.005x |
Annual Cash Flow Conversion Efficiency for Lifecare AS (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lifecare AS from 2017 to 2025. Review Lifecare AS (LIFE) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr-28.02 Million ≈ $-2.95 Million |
Nkr-110.37 Million ≈ $-11.61 Million |
3.939x | +544.67% |
| 2024-12-31 | Nkr73.98 Million ≈ $7.78 Million |
Nkr-65.54 Million ≈ $-6.90 Million |
-0.886x | -63.52% |
| 2023-12-31 | Nkr66.45 Million ≈ $6.99 Million |
Nkr-36.00 Million ≈ $-3.79 Million |
-0.542x | -67.72% |
| 2022-12-31 | Nkr55.25 Million ≈ $5.81 Million |
Nkr-17.85 Million ≈ $-1.88 Million |
-0.323x | +43.13% |
| 2021-12-31 | Nkr24.25 Million ≈ $2.55 Million |
Nkr-13.77 Million ≈ $-1.45 Million |
-0.568x | -170.03% |
| 2020-12-31 | Nkr13.33 Million ≈ $1.40 Million |
Nkr-2.80 Million ≈ $-294.99K |
-0.210x | +50.64% |
| 2019-12-31 | Nkr15.73 Million ≈ $1.66 Million |
Nkr-6.70 Million ≈ $-705.49K |
-0.426x | -41.36% |
| 2018-12-31 | Nkr22.24 Million ≈ $2.34 Million |
Nkr-6.70 Million ≈ $-705.49K |
-0.301x | -110.57% |
| 2017-12-31 | Nkr-2.35 Million ≈ $-247.41K |
Nkr-6.70 Million ≈ $-705.49K |
2.852x | -- |
About Lifecare AS
Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway and United Kingdom. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifeca… Read more